Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IPO hope for post-Novartis antibiotic developer Paratek

This article was originally published in Scrip

Executive Summary

Paratek Pharmaceuticals has filed initial registration documents for an IPO in a move that signals hope for its Phase III-ready novel antibiotic omadacycline. The firm was down to $3.3 million in cash and cash equivalents at the end of June, and its development programme had effectively been stalled by the withdrawal of Novartis less than two years into their partnership for the product, formerly known as PTK0796, last August.

You may also be interested in...



Paratek's Antibiotic Nuzyra Survived 20 Years – Now For The US Launch

Company still mulling pricing for broad-spectrum antibiotic Nuzyra (omadacycline), which is set to launch in the US in the first quarter, following FDA approval Oct. 2.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet

Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

Related Companies

Latest News
UsernamePublicRestriction

Register

SC018937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel